Active Cluster Of Differentiation 55 (CD55) Homo sapiens (Human) Active protein

DAF; CR; TC; Complement decay-accelerating factor; Decay Accelerating Factor

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point5.9
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Cluster Of Differentiation 55 (CD55) Packages (Simulation)
  • Active Cluster Of Differentiation 55 (CD55) Packages (Simulation)
  • APA468Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Cluster Of Differentiation 55 (CD55), also known as Decay Accelerating Factor (DAF), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that belongs to the RCA (regulators of complement activation) family and is expressed on all cells that are bathed in plasma, such as blood cells and endothelial cells. CD55 functions as a complement regulator, accelerating the decay of C3 and C5 convertases, thereby inhibiting the formation of the membrane attack complex (MAC) and preventing complement-mediated cell lysis. It plays a crucial role in protecting host cells from complement damage and is involved in various physiological and pathological processes, including immune complex clearance and inflammation.When CD55 binds to C4a, CD55 can regulate the activity of the complement system and prevent cell damage caused by over-activation of the complement.. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human CD55 and recombinant human C4a. Briefly,CD55 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to C4a-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-CD55 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human CD55 and recombinant human C4a was shown in Figure 1, the EC50 for this effect is0.18ug/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Role of IL-1ra and Granzyme B as biomarkers in active Crohn's disease patientspubmed:28972805
  • Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions34397724

Recommend products